Wednesday, July 26, 2017
 
 
Company News: Page (1) of 1 - 02/17/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
New Data Shows STELARA® (ustekinumab) Maintained Clinical Response and Remission after Two Years of Treatment in Patients with Moderate to Severe Crohns Disease

(February 17, 2017)
Our Apologies, This article is no longer available, You may have followed an outdated link.


Page: 1


Related Keywords:
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
Seniors

Drugs
  • Global Neuropsychiatric Disorders And Treatment Market Is Expected To Grow At A CAGR Of 6.2% During Forecast 2023
  • Urology Devices Global Market - Forecast to 2023
  • ChiRhoStim® (Human Secretin for Injection) FDA approved labeling update and 5-year shelf life approval
  • Wound Closure and Advanced Wound Care Global Market Forecast To 2023
  • Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress

    Cancer
  • Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
  • Asia-Pacific Immunodiagnostics Analyzers and Reagents Market 2021: A 17-Country Analysis--Supplier Strategies, Volume and Sales Forecasts, Technology and Instrumentation Review
  • Varian to Showcase Latest Radiotherapy and Radiosurgery Technologies and Software at AAPM 2017
  • American Brain Tumor Association's Annual Patient and Family Conference to Address Physical and Cognitive Symptoms and Side Effects
  • St. Jude Children's Research Hospital®, ALSAC Announce Chairs of Boards of Directors and Governors
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines